Mode
Text Size
Log in / Sign up
N/A N=127 Randomized Triple-blind Basic Science

Cocaine Use Reduction and Health

Cocaine Use Disorder

Enrolled (actual)
127
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcome: Primary: Endothelin-1 Levels — 2.15; 2.063; 1.956 pg/ml

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Contingency Management (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
William Stoops
Primary completion
Jan 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Endothelin-1 Levels
2.093; 2.083; 2.086
PRIMARY
Endothelin-1 Levels
2.093; 2.083; 2.086
PRIMARY
Endothelin-1 Levels
2.093; 2.083; 2.086
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
PRIMARY
Mean Arterial Pressure
97.98; 102.10; 93.05
SECONDARY
Interleukin-10
.384; .481; .230
SECONDARY
Interleukin-10
.384; .481; .230
SECONDARY
Interleukin-10
.384; .481; .230
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Total Sleep Time
435; 378.23; 387.05
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Hamilton Depression Scale Score
1; 0; 0
SECONDARY
Criteria for Cocaine Use Disorder Diagnosis
6.2; 4.8; 6.5
SECONDARY
Criteria for Cocaine Use Disorder Diagnosis
6.2; 4.8; 6.5
SECONDARY
Reactive Hyperemia Index
.53; .81; .42
SECONDARY
Reactive Hyperemia Index
.53; .81; .42

Summary

Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced cocaine use. These data will be used to change current accepted cocaine treatment endpoints and accelerate identification of therapies for cocaine use disorder.

Eligibility Criteria

Inclusion Criteria

  • Age 18 or older
  • Self-report of recent cocaine use verified by a cocaine-positive urine sample
  • Meet moderate-severe Cocaine Use Disorder Criteria
  • Seeking treatment for their cocaine use
  • Able to commit to 12-week intervention, plus 24-week follow up

Exclusion Criteria

  • History of serious physical or psychiatric disease (e.g., physical dependence on any drug requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, extreme hypersensitivity/allergy to candida yeast or similar products, severe diagnosis for other substance use disorder) that would interfere with study participation
  • Current physical or psychiatric disease that would interfere with study participation
  • Poor veinous access, precluding blood draws
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03224546). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search